Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis. by Shamshirian, A et al.
RESEARCH ARTICLE Open Access
Diagnostic value of serum HER2 levels in
breast cancer: a systematic review and
meta-analysis
Amir Shamshirian1,2, Amir Reza Aref3*, George W. Yip4, Majid Ebrahimi Warkiani5,6, Keyvan Heydari2,7,
Sajad Razavi Bazaz5, Zeinab Hamzehgardeshi8, Danial Shamshirian9, Mahmood Moosazadeh10 and
Reza Alizadeh-Navaei2*
Abstract
Background: Measurement of serum human epidermal growth factor receptor-2 (HER-2/neu) levels might play an
essential role as a diagnostic/screening marker for the early selection of therapeutic approaches and predict
prognosis in breast cancer patients. We aimed to undertake a systematic review and meta-analysis focusing on the
diagnostic/screening value of serum HER-2 levels in comparison to routine methods.
Methods: We performed a systematic search via PubMed, Scopus, Cochrane-Library, and Web of Science databases
for human diagnostic studies reporting the levels of serum HER-2 in breast cancer patients, which was confirmed
using the histopathological examination. Meta-analyses were carried out for sensitivity, specificity, accuracy, area
under the ROC curve (AUC), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio
(PLR), and negative likelihood ratio (NLR).
Results: Fourteen studies entered into this investigation. The meta-analysis indicated the low sensitivity for serum
HER2 levels (Sensitivity: 53.05, 95%CI 40.82–65.28), but reasonable specificity of 79.27 (95%CI 73.02–85.51), accuracy
of 72.06 (95%CI 67.04–77.08) and AUC of 0.79 (95%CI 0.66–0.92). We also found a significant differences for PPV
(PPV: 56.18, 95%CI 44.16–68.20), NPV (NPV: 76.93, 95%CI 69.56–84.31), PLR (PLR: 2.10, 95%CI 1.69–2.50) and NLR (NLR:
0.58, 95%CI 0.44–0.71).
Conclusion: Our findings revealed that although serum HER-2 levels showed low se nsitivity for breast cancer
diagnosis, its specificity, accuracy and AUC were reasonable. Hence, it seems that the measurement of serum HER-2
levels can play a significant role as a verification test for initial negative screening test results, especially in low-
income regions due to its cost-effectiveness and ease of implementation.
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Background
The most common deadly cancer among women is
breast cancer throughout the world; this condition is
more severe in developing countries [1, 2]. As a hetero-
geneous complex disease, this malignancy includes dif-
ferent subtypes with different clinical outcomes and
treatment responses [3]. Previous investigations showed
that the early detection and diagnosis of this malignancy
could lead to promising treatment and improve the
chance of successful therapy [4]. In this regard, there are
different types of diagnostic approaches for the detection
of breast cancer, such as magnetic resonance imaging
(MRI) of the breast, mammography, molecular imaging,
biopsy, and ultrasound tomography [5].
The human epidermal growth factor receptor-2 (HER-
2/neu) or c-erbB-2/neu is one of the epidermal growth
factor receptor (EGFR) family members. As an onco-
gene, the amplification of HER-2 or its protein overex-
pression has a significant role in the development of
malignant types of breast cancer, which observes in 20–
30% of breast cancer patients [6, 7]. Remarkably, Slamon
et al. [8] have understood the importance of HER-2 as a
diagnostic factor for breast cancer in 1987. Recently, this
protein has gained significant attention as a biomarker
as well as a target of diagnosis, prognosis, and therapy in
breast cancer patients [9].
There are several methods to determine the presence
of HER-2, which are 1. gene copy measuring by poly-
merase chain reaction (PCR), Southern blot analysis,
Chromogenic In Situ Hybridization (CISH) and Fluores-
cence In Situ hybridization (FISH); 2. messenger RNA
measuring by PCR or Southern blot analysis; 3. protein
expression measuring by Western blot and Immunohis-
tochemical (IHC) analysis; and 4. serum antigen measur-
ing by Enzyme-Linked Immunosorbent Assay (ELISA)
or chemiluminescence immunoassays (CLIA). It is highly
recommended to use IHC for the evaluation of HER2
status. In this regard, IHC scored 3+ would be consid-
ered as positive status and 0/1+ as a negative status. In
this way, score 2+ is uncertain and should be confirmed
through FISH as a gold standard [10, 11].
The HER-2 protein contains three different do-
mains, including transmembrane, extracellular, and
intracellular tyrosine kinase domain. The extracellular
domain (ECD) can be released into the blood after
cleavage and shedding from the tumor cell surface by
metalloproteases [12, 13]. Therefore, it can be de-
tected in the serum. Serum HER-2 levels increase in
18% of primary breast cancers and 46% of metastatic
breast cancers [14, 15]. There are several shreds of
evidence regarding the correlation of serum HER-2
levels and tissue HER-2 protein overexpression as well
as poor prognosis in a metastatic type of breast can-
cer [16–19].
Nevertheless, the most effective method for HER-2
measurement is controversial in the case of efficacy and
ease of implementation [7]. In fact, several discrepancies
between utilization of serum or tissue HER2 have raised
to the researchers in the field such as a shortage in de-
fining tissue positivity for HER2 due to classification sys-
tem, heterogeneity of breast cancers, conversion of
HER2 status and the kinetic nature of serum HER2 ECD
concentrations, cut-off levels, serum interference, etc.
[20]. Following such disagreements, measurement of
serum HER-2 level is not recommended in any clinical
procedure according to the “American Society of Clinical
Oncology (ASCO) 2007 update of recommendations for
the use of tumor markers in breast cancer” [21].
However, over time, it seems that HER-2 measuring
can play an important role as a diagnostic marker or at
least screening marker for the early selection of thera-
peutic approaches as well as predict prognosis in breast
cancer patients. In fact, any carelessness regarding HER2
status can change the treatment approach. Regardless of
therapies’ side effects, it will have a high-cost burden on
patients and endangering their lives. Hence, we aimed to
undertake a systematic review and meta-analysis focus-
ing on the diagnostic/screening values of serum HER-2
levels compared to reference methods of FISH/IHC due
to its ease of application and cost-effectiveness. We hope
our findings could help the controversies on the subject
and be useful for the new update of recommendations
for the use of tumor markers in breast cancer.
Method
Search strategy
In order to study design, search strategy, screening, and
reporting, we followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines. We performed a systematic search via PubMed,
Scopus, Cochrane Library, and Web of Science databases
up to 15 February 2019. The search strategy included
MeSH terms and free keywords as follows: ((Breast OR
Mammary) AND (Cancer* OR Neoplasm* OR Tumor*
OR Malignancy* OR Carcinoma*) AND (HER2* OR
erbB2*) AND (Sensitivity* OR Specificity*) AND Serum).
Our search was restricted to English papers, but there
was no limitation regarding the date of publications.
Only human diagnostic studies on breast cancer without
criteria for the types were included.
Criteria study selection
Two members of our group (A.SH and R.AN) selected
the studies independently and discussed to solve the dis-
agreements. Inclusion and exclusion criteria are pre-
sented in Table 1.
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Data extraction & quality assessment
Two investigators (A.SH and K.HD) have independently
assessed the quality of studies and extracted data from
included papers. The supervisor (R.AN) resolved any
disagreements in this part. Data extraction checklist in-
cluded the name of first author, publication year, num-
ber of patients, mean age, histopathological results,
serum HER2 level, area under the ROC Curve (AUC),
true positives (TP), true negatives (TN), false positives
(FP) and false negatives (FN) of serum HER2 level, clini-
copathological features, and available correlations. To
assess the quality of included studies, Quality Assess-
ment of Diagnostic Accuracy Studies (QUADAS-2) tool
was used.
Data analysis
Sensitivity, specificity, positive predictive values (PPV),
negative predictive values (NPV), positive likelihood ra-
tio (PLR), negative likelihood ratio (NLR), and accuracy
and 95% confidence interval were calculated with Med-
calc. Statistical analysis was performed using STATA
v.11 software. To assess the heterogeneities, we used I-
square (I2) test. According to extreme heterogeneity, the
random-effects model was used for the calculation of
pooled estimation. For the finding of suspected parame-
ters for heterogeneity, we used sensitivity analysis as well
for serum level cut-off. The possible publication bias
was evaluated using Egger’s asymmetry test, which pre-
sented by the funnel plot. P-values less than 0.05 were
considered statistically significant.
Ethical approval
Study protocol has been registered in the International
Prospective Register of Systematic Reviews (PROSPERO)
due to code CRD42019126703.
Results
Study selection process
Our initial database search contained 1066 papers. After
removing duplicated articles, we used the title and ab-
stract for screening remaining studies. Finally, 77 papers
considered for eligibility assessment, of which 14 studies
entered into the meta-analysis. The PRISMA flow dia-
gram for the study selection process is presented in Sup-
plementary Fig. 1.
Study characteristics
Out of selected studies, a total of 3528 breast cancer pa-
tients with age ranged between 25 to 93 were included
in our study. The cut-off value was set at 15.0 ng/ml for
serum-HER2 concentration in most of the studies, ac-
cording to the Food and Drug Administration (FDA)
and various manufacturer’s recommendations for breast
cancer. Seven studies used CLIA, five studies used
ELISA, and two studies used both methods for the de-
termination of serum-HER2 levels. Characteristics of
studies entered into meta-analysis are presented in
Table 2.
Quality assessment
According to quality assessment using the QUADAS-2
tool, 14 papers earned the eligibility score and entered
into the meta-analysis. The quality assessment graph
and methodological quality summary are presented in
Supplementary Fig. 2 and 3.
Egger’s test
Egger’s test indicated a significant publication bias for
serum sensitivity (P = 0.001), specificity (P = 0.009), PPV
(P = 0.019), and NLR (P = 0.001). Publication bias for
NPV (P = 0.073), PLR (P = 0.084), accuracy (P = 0.086),
and AUC was not significant (P = 0.169).
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
• human diagnostic studies reported the level of serum HER2 in breast cancer patients • Non-human subjects
• Studies confirmed the breast cancer using immunohistopathological examination • Conference abstracts
• Studies reported the sensitivity and specificity of serum HER2 level or comprised with data could to calculate the
desiered parameters mentioned in data extraction section
• Grey literature
• Comments
• Full text published papers • Letters
• English language • Reviews
• Case reports
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Main outcomes
Sensitivity (Fig. 1)
Carrying meta-analysis on 14 studies indicated a low
sensitivity for serum-HER2 measurement in comparison
to histopathological examinations (Sensitivity: 53.05,
95%CI 40.82–65.28). Significant heterogeneity was ob-
served (I2 = 94.0%, P < 0.0001). Sensitivity analysis using
the same cut-offs indicated no significant deferences
(Sensitivity: 51.49, 95%CI 35.27–67.71) (Supplementary
Fig. 4).
Specificity (Fig. 2)
According to meta-analysis of 13 papers’ outcomes, findings
revealed a substantial specificity for the measurement of
serum-HER2 in breast cancer diagnosis (Specificity: 79.27,
95%CI 73.02–85.51). The heterogeneity was considerable
Table 2 Characteristics of studies entered into the meta-analysis
Author Year Country No. of cases Reference method Detection method Cut-off value
Kong [17] 2006 Korea 195 IHC/FISH CLIA 15 μg/L
Olsen [22] 2007 Germany 118 IHC/FISH ELISA/ CLIA 15 ng/mL
Ludovini [23] 2008 Italy 256 IHC/FISH ELISA/ CLIA 15 ng/mL
Papadopoulou [24] 2008 Greece 56 a ELISA 1.98 ng/ml
Savino [25] 2009 Italy 85 IHC ELISA 22 ng/mL
Finn [26] 2009 – 579 IHC/FISH ELISA 16 ng/mL
Farzadnia [27] 2010 Iran 75 IHC ELISA 18.4 ng/ml
Lauterlein [28] 2011 Denmark 311 IHC/FISH CLIA 12.2 mg/L
Sørensen [29] 2013 Denmark 540 IHC/FISH CLIA 15 μg/L
Pedersen [30] 2013 Denmark 107 IHC/FISH CLIA 15 μg/L
Di Gioia [31] 2014 Germany 565 IHC/FISH CLIA 15 ng/mL
Di Gioia [32] 2015 Germany 241 IHC/FISH CLIA 15 ng/mL
Banys-Paluchowski [33] 2017 Germany 251 IHC/FISH ELISA 15 ng/mL
Broughton [34] 2017 Norway 149 IHC/FISH CLIA 15.2 μg/L
IHC Immunohistochemistry, FISH Fluorescence in situ hybridization, CLIA Chemiluminescence immunoassay, ELISA Enzyme-linked immunosorbent assay, a only
mentioned histological examination
Fig. 1 Forest plot for serum-HER2 sensitivity
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(I2 = 93.8%, P < 0.0001). Sensitivity analysis using the
same cut-offs indicated no significant deferences
(Specificity: 81.52, 95%CI 73.48–89.56) (Supplemen-
tary Fig. 5).
PPV & NPV (Fig. 3)
Considering the performance of a diagnostic test, our
meta-analysis demonstrated the PPV of 56.18 (95%CI
44.16–68.20) and the NPV of 76.93 (95%CI 69.56–84.31)
for serum-HER2 examination. The heterogeneity was sig-
nificant for both PPV and NPV (I2 = 94.4%, P < 0.0001,
I2 = 98.5%, P < 0.0001, respectively). Sensitivity analysis
using the same cut-offs indicated no significant deferences
for both PPV (PPV: 58.37, 95%CI 43.74–73.00) (Supple-
mentary Fig. 6) and NPV (NPV: 78.08, 95%CI 67.19–
88.96) (Supplementary Fig. 7).
PLR & NLR (Fig. 4)
Regarding value of performing a diagnostic test, meta-
analysis found the significant PLR 2.10 (95%CI 1.69–
2.50) and NLR 0.58 (95%CI 0.44–0.71) for the serum-
HER2 test. The high heterogeneity was observed for
Fig. 2 Forest plot for serum-HER2 specificity
Fig. 3 Forest plot for serum-HER2 Positive Predictive Value (A) and Negative Predictive Value (B)
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both PLR and NLR (I2 = 57.7%, P = 005, I2 = 90.6%,
P < 0.0001, respectively). Sensitivity analysis using the
same cut-offs indicated no significant deferences for
both PLR (PLR: 2.33, 95%CI 1.72–2.95) (Supplemen-
tary Fig. 8) and NLR (NLR: 0.56, 95%CI 0.38–0.74)
(Supplementary Fig. 9).
Accuracy (Fig. 5)
By examining sensitivity and specificity, we found
the accuracy of 72.06 (95%CI 67.04–77.08) for this
biomarker. Substantial heterogeneity was observed
(I2 = 90.0%, P < 0.0001). Sensitivity analysis using the
same cut-offs indicated no significant deferences
(Accuracy: 73.12, 95%CI 56.68–80.56) (Supplemen-
tary Fig. 10).
Area under the ROC curve (Fig. 6)
Considering the AUCs that could be extracted only from
three studies, meta-analyses of AUCs resulted in overall
AUC of 0.79 (95%CI 0.66–0.92). The heterogeneity was
significant (I2 = 87.6%, P < 0.0001).
Fig. 4 Forest plot for serum-HER2 Positive Likelihood Ratio (A) and Negative Likelihood Ratio (B)
Fig. 5 Forest plot for serum-HER2 accuracy
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Meta-regression analysis
To find the impact of moderator variables on heteroge-
neities, meta-regression analysis considering publication
year (P = 0.31), mean age (P = 0.72), and metastatic/non-
metastatic condition (P = 0.79) resulted in no significant
relationships.
Discussion
According to all controversies regarding the diagnostic/
screening value of serum-HER2 in breast cancer, to
overcome this debate, we conducted a meta-analysis to
integrate the results of studies included with adequate
data for calculation of the test’s accuracy in this regard.
Finally, we found that serum-HER2 indicated a high spe-
cificity for detecting tissue HER2 status in breast cancer.
In detail, specificity for a screening test can be defined
as the test’s ability to identify the true negative cases or,
in other words, identifying all cases which do not have
the target disorder based on the performance relative to
a gold standard [35]. Accordingly, our meta-analysis in-
dicated the specificity 79.27 (95%CI 73.02–85.51) for the
serum-HER2 test, the test’s ability to detect individuals
with the negative result based on the presence/absence
of breast cancer is high and satisfactory.
In order to apply appropriate treatments for a disorder,
we mainly need to more accurate diagnostic tests, especially
with the development of modernity toward higher speed,
cost-effectiveness, performance, and safety, which resulted
in several available diagnostic tests for a particular condi-
tion [36]. Focusing on our study, in several cancers, HER2
status is a necessary item for HER2 targeted therapy, which
mostly will be determined using biopsy specimens. The
biopsy problem is that it is not always easily available, and
the expression of HER2 is heterogeneous within tumor
tissue, which might lead to a false negative outcome [37].
Also, given our experiences, other limitations might affect
the results as follows: 1. The lab is not equipped for
running this test; 2. The cancer is HER2 negative; and 3.
The tumor is small, and therefore, the amount of HER2
that is shed into the bloodstream is limited.
Among all available HER-2 examination methods, IHC
and FISH were the most preferred techniques among
clinicians and researchers [38]. However, the desire for
the measurement of serum-HER2 levels as a non-invasive
technique for breast cancer diagnosis and prognosis has
attracted the investigators’ interests in two recent decades
[39, 40].
In more detail, sensitivity for a screening test can be
defined as the test’s ability to identify the true positive
cases or, in other words, identifying all cases with the
considered disorder based on performance relative to a
gold standard [35]. Accordingly, our findings showed a
sensitivity of 53.05 (95%CI 40.82–65.28) for the serum-
HER2 test; the ability of the test for detection of
individuals with a positive result based on reference
standard is low and unsatisfactory.
From another point of view, the indicator PPV demon-
strates that how many people tested positive based on the
screening test are actually have the considered condition
[35]. In this regard, our meta-analysis showed the PPV
56.18 (95%CI 44.16–68.20), which is low as like as sensitiv-
ity for the serum-HER2 test and suggest unsatisfactory per-
formance for this test in comparison to the gold standard.
Moreover, the indicator NPV indicates that how many
people tested negative based on screening tests truly do
not have the target condition. In this regard, our findings
showed the NPV 76.93 (95%CI 69.56–84.31), which is
high as like as specificity for the serum-HER2 test and
suggest satisfactory performance for this test in compari-
son to the gold standard.
Altogether, owing mentioned metrics, another metric
is proposed as a diagnostic test accuracy or effectiveness,
Fig. 6 Forest plot for Area under the ROC Curve
Shamshirian et al. BMC Cancer         (2020) 20:1049 Page 7 of 10
which is defined as the test’s ability to differentiate
between subjects with or without the target disorder. In
other words, the test’s ability to classify true positive and
negative subjects among all subjects [41, 42]. Our results
revealed the accuracy of 72.06 (95%CI 67.04–77.08) for
the serum-HER2 test, which is reasonably high and
suggests satisfactory performance in this regard.
It is worth mentioning that the prevalence of the target
condition affects the diagnostic accuracy of the test. If the
sensitivity and specificity do not change, the accuracy of
the test will increase by decreasing condition prevalence
[43].
As an alternative statistic, positive and negative likeli-
hood ratios are powerful metrics for diagnostic accuracy
summarising [44]. The likelihood ratio defines as the
probability of test results in subjects with the condition to
the probability in the subjects without the condition [45].
In this regard, our findings demonstrated that PLR 2.10
(95%CI 1.69–2.50) and NLR 0.58 (95%CI 0.44–0.71) for
the serum-HER2 test, which shows an association with
the presence and absence of the condition, respectively.
However, it is reported that PLR greater than 10 and NLR
less than 0.1 provide strong evidence for diagnosis [46].
It is significant that if the entered studies into meta-
analysis use different cut-off values for presenting positive
results for a test, the threshold effect will arise toward bias
[47]. We conducted the sensitivity analysis on studies with
the same cut-off values to avoid the bias, which revealed
no significant differences (Supplementary File).
As far as we know, this meta-analysis demonstrates the
first report of evaluating the diagnostic/screening values of
serum-HER2 in breast cancer patients. In this regard,
Zhang et al. [48] study has indicated a high specificity and
moderate diagnostic value for serum-HER2 in gastric
cancer patients as a potential surrogate biomarker of HER2
status.
Considering all the facts mentioned above, although
the serum-HER2 test has failed to be considered as a
gold standard test, according to the shreds of evidence,
this test can be beneficial for the detection of true nega-
tives (HER2 negative status, or absence of breast cancer),
especially in low-income regions due to its cost-
effectiveness and ease of implementation. However, fur-
ther extensive prospective studies are needed to robust
the findings of this study. Also, monitoring serum-HER2
concentrations during treatment and tumor progression
is recommended to find the prognosis values of serum-
HER2 in such patients.
Given the fact that limitations are unavoidable and all
studies face that, as a potential limitation in the present
study, although most studies used the same cut-off
values since we had no access to raw data, we could not
define an ideal threshold for the serum-HER2 test in the
diagnosis of breast cancer.
Conclusion
As far as we know, this systematic review and meta-
analysis is the first report regulated numerical data in
order to find the diagnostic values of serum-HER2 test
in breast cancer. Our findings indicated that, although
serum HER2 levels showed low sensitivity for breast can-
cer diagnosis, its specificity is significantly high. Hence,
it seems that the measurement of serum HER2 levels
can play a significant role as a verification test for initial
negative screening test results, especially in low-income
regions due to its cost-effectiveness and ease of
implementation.
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